These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 20623619)

  • 1. Novel D3 dopamine receptor-preferring agonist D-264: Evidence of neuroprotective property in Parkinson's disease animal models induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and lactacystin.
    Li C; Biswas S; Li X; Dutta AK; Le W
    J Neurosci Res; 2010 Aug; 88(11):2513-23. PubMed ID: 20623619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease.
    Li C; Guo Y; Xie W; Li X; Janokovic J; Le W
    Neurochem Res; 2010 Oct; 35(10):1546-56. PubMed ID: 20635141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
    Savolainen MH; Albert K; Airavaara M; Myöhänen TT
    Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
    Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
    Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
    Price DA; Martinez AA; Seillier A; Koek W; Acosta Y; Fernandez E; Strong R; Lutz B; Marsicano G; Roberts JL; Giuffrida A
    Eur J Neurosci; 2009 Jun; 29(11):2177-86. PubMed ID: 19490092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.
    Du F; Li R; Huang Y; Li X; Le W
    Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system x
    Bentea E; Van Liefferinge J; Verbruggen L; Martens K; Kobayashi S; Deneyer L; Demuyser T; Albertini G; Maes K; Sato H; Smolders I; Lewerenz J; Massie A
    Exp Neurol; 2017 Apr; 290():15-28. PubMed ID: 28024798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators.
    Zhu W; Xie W; Pan T; Xu P; Fridkin M; Zheng H; Jankovic J; Youdim MB; Le W
    FASEB J; 2007 Dec; 21(14):3835-44. PubMed ID: 17690154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
    Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
    Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
    Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
    J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration.
    Zhu W; Xie W; Pan T; Jankovic J; Li J; Youdim MB; Le W
    J Neurochem; 2008 Jun; 105(5):1970-8. PubMed ID: 18399960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.
    Joyce JN; Woolsey C; Ryoo H; Borwege S; Hagner D
    BMC Biol; 2004 Oct; 2():22. PubMed ID: 15473914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain.
    Wąsik A; Romańska I; Zelek-Molik A; Nalepa I; Antkiewicz-Michaluk L
    Neurotox Res; 2018 Oct; 34(3):706-716. PubMed ID: 30129004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
    Joyce JN; Presgraves S; Renish L; Borwege S; Osredkar T; Hagner D; Replogle M; PazSoldan M; Millan MJ
    Exp Neurol; 2003 Nov; 184(1):393-407. PubMed ID: 14637109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease.
    Xie W; Li X; Li C; Zhu W; Jankovic J; Le W
    J Neurochem; 2010 Oct; 115(1):188-99. PubMed ID: 20649845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrastriatal transplantation of GDNF-engineered BMSCs and its neuroprotection in lactacystin-induced Parkinsonian rat model.
    Wu J; Yu W; Chen Y; Su Y; Ding Z; Ren H; Jiang Y; Wang J
    Neurochem Res; 2010 Mar; 35(3):495-502. PubMed ID: 19894114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal and subcutaneous administration of dopamine D3 receptor agonists functionally restores nigrostriatal dopamine in MPTP-treated mice.
    Lao CL; Kuo YH; Hsieh YT; Chen JC
    Neurotox Res; 2013 Nov; 24(4):523-31. PubMed ID: 23820985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
    Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
    J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.